Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 461Neoplasms 378Carcinoma, Non-Small-Cell Lung 354Prostatic Neoplasms 294Colorectal Neoplasms 257Lung Neoplasms 225Multiple Myeloma 206Neoplasm Metastasis 164Pancreatic Neoplasms 156Leukemia, Myeloid, Acute 153Ovarian Neoplasms 136Squamous Cell Carcinoma of Head and Neck 130Melanoma 116Carcinoma, Renal Cell 103Stomach Neoplasms 102Carcinoma, Hepatocellular 100Recurrence 98Lymphoma 94Precursor Cell Lymphoblastic Leukemia-Lymphoma 92Head and Neck Neoplasms 91Lymphoma, Non-Hodgkin 86Glioblastoma 85Brain Neoplasms 84Hematologic Neoplasms 83Urinary Bladder Neoplasms 82Triple Negative Breast Neoplasms 81Endometrial Neoplasms 80Lymphoma, Large B-Cell, Diffuse 79Leukemia, Lymphocytic, Chronic, B-Cell 77Uterine Cervical Neoplasms 74

Interventions

Olanzapine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Vomiting × 30 days × Clear all
NCT07403370 2026-05-19

Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

Shandong Cancer Hospital and Institute

Completed
2,000 enrolled

Nausea, Vomiting

NCT07581119 2026-05-12

MANDALACHEMO

University of Gaziantep

Phase NA Completed
85 enrolled

Psychological Well-Being, Fatigue, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡